Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Pate A, Lowery J, Kilbourn K, Blatchford PJ, McNulty M, Risendal B. Quality of life and the negative impact of comorbidities in long-term colorectal cancer survivors: a population-based comparison. J Cancer Surviv 2020;14:653-659. [PMID: 32394045 DOI: 10.1007/s11764-020-00876-w] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Accepted: 03/05/2020] [Indexed: 12/26/2022]

For:	Pate A, Lowery J, Kilbourn K, Blatchford PJ, McNulty M, Risendal B. Quality of life and the negative impact of comorbidities in long-term colorectal cancer survivors: a population-based comparison. J Cancer Surviv 2020;14:653-659. [PMID: 32394045 DOI: 10.1007/s11764-020-00876-w] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Accepted: 03/05/2020] [Indexed: 12/26/2022]

Number

Cited by Other Article(s)

Esteva M, March S, Martín-Rabadan M, Torres-Solera E, Ripoll J. Health-related quality of life and lifestyle in long-term survivors of colorectal cancer and a matched non-cancer reference group. Clin Transl Oncol 2025:10.1007/s12094-025-03930-0. [PMID: 40299301 DOI: 10.1007/s12094-025-03930-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2024] [Accepted: 04/06/2025] [Indexed: 04/30/2025]

Abstract

OBJECTIVE

To compare the long-term health status of a group of survivors of colorectal cancer (CRC) with a reference group of individuals who did not have cancer. We determined the physical, mental, and general health-related quality of life (HRQoL); overall morbidities and CRC-specific morbidities related to the delayed effects of treatment; and maintenance of a healthy lifestyle in these two groups.

METHODS

This descriptive cross-sectional study was conducted from 2016 to 2019 in the Balearic Islands (Spain). CRC patients who were diagnosed from 2011 to 2012 and survived at least 5 years were randomly selected from the Majorca and Eivissa-Formentera cancer registries. The reference group consisted of individuals matched for gender and age who had no history of cancer.

RESULTS

We examined 201 CRC survivors and 199 matched individuals without cancer. The global analysis showed that the two groups had similar scores in the physical and mental components of the Short Form 12 (SF-12) HRQoL scale and in general health status. The CRC survivors had significantly higher prevalence of general comorbidity and CRC-specific comorbidity. Multivariate analyses and calculation of odds ratios (ORs) showed that the groups had similar physical HRQoL (Model 1, OR: 1.01, 95% CI: 0.99-1.03), mental HRQoL (Model 2, OR: 0.99, 95% CI: 0.66-1.01), and general HRQoL (Model 3, OR: 1.67, 95% CI: 0.39-1.13). However, the long-term CRC survivors had significantly greater ORs for an increased overall comorbidity index, number of CRC-specific comorbidity, and obesity in all three models (P < 0.05).

CONCLUSIONS

The CRC survivors and individuals without cancer had similar HRQoL, suggesting that CRC survivors do not need additional services that aim to improve HRQoL. Nonetheless, health care providers should be pro-active when caring for CRC survivors, because they are more likely to present with certain comorbidity and less likely to follow a healthy lifestyle.

Collapse

Zou M, Xu J, Chen F, Wang N, Long S, Wu H, Wang W, Zhang X, Zeng C, Chen L, Zhang L, Zhang X. A qualitative exploration of perioperative subjective experiences of colorectal cancer patients undergoing fast-track surgery. Sci Rep 2024;14:30721. [PMID: 39730444 DOI: 10.1038/s41598-024-79944-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2024] [Accepted: 11/13/2024] [Indexed: 12/29/2024] Open

Marcos-Delgado A, Martín-Sánchez V, Molina-Barceló A, Alonso-Molero J, Pérez-Gómez B, Pollán M, Aragonés N, Ederra-Sanza M, Fernández-Tardón G, Binefa G, Moreno V, Barrios-Rodríguez R, Amiano P, Huerta JM, Teso EP, Alguacil J, Castaño-Vinyals G, Kogevinas M, Molina de la Torre AJ. Health-Related Quality of Life in Long-Term Colorectal Cancer Survivors. Healthcare (Basel) 2024;12:1917. [PMID: 39408097 PMCID: PMC11475455 DOI: 10.3390/healthcare12191917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2024] [Revised: 09/10/2024] [Accepted: 09/18/2024] [Indexed: 10/20/2024] Open

Affiliation(s)

Alba Marcos-Delgado The Research Group in Gene-Environment and Health Interactions, Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (V.M.-S.); (A.J.M.d.l.T.) Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, 24071 León, Spain CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.)
Vicente Martín-Sánchez The Research Group in Gene-Environment and Health Interactions, Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (V.M.-S.); (A.J.M.d.l.T.) Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, 24071 León, Spain CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.)
Ana Molina-Barceló Cancer and Public Health Area, FISABIO-Public Health, 46022 Valencia, Spain;
Jessica Alonso-Molero CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Department of Preventive Medicine and Public Health, IDIVAL, Universidad de Cantabria, 39005 Cantabria, Spain
Beatriz Pérez-Gómez CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain
Marina Pollán CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain
Nuria Aragonés CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain
María Ederra-Sanza CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Navarra Public Health Institute, 31003 Pamplona, Spain IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain
Guillermo Fernández-Tardón CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) ISPA (Health Research Institute of the Pincipality of Asturias), IUOPA, University of Oviedo, 33006 Asturias, Spain
Gemma Binefa CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, 08901 Barcelona, Spain Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain
Victor Moreno CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, 08901 Barcelona, Spain Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain
Rocío Barrios-Rodríguez CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, 18071 Granada, Spain Instituto de Investigación Biosanitaria ibs, 18012 Granada, Spain
Pilar Amiano CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Public Health Division of Gipuzkoa, Biodonostia Research Institute, 20014 San Sebastian, Spain
José María Huerta CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, 30120 Murcia, Spain
Enrique Pastor Teso Servicio de Cirugía General y del Aparato Digestivo, Complejo Asistencial Universitario de León, 24008 León, Spain;
Juan Alguacil CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, 21004 Huelva, Spain
Gemma Castaño-Vinyals CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Instituto de Salud Global de Barcelona (ISGlobal), 08036 Barcelona, Spain Campus del Mar, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
Manolis Kogevinas CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.) Instituto de Salud Global de Barcelona (ISGlobal), 08036 Barcelona, Spain Campus del Mar, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
Antonio José Molina de la Torre The Research Group in Gene-Environment and Health Interactions, Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (V.M.-S.); (A.J.M.d.l.T.) Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, 24071 León, Spain CIBER Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain; (J.A.-M.); (B.P.-G.); (M.P.); (N.A.); (M.E.-S.); (G.F.-T.); (G.B.); (V.M.); (R.B.-R.); (P.A.); (J.M.H.); (J.A.); (G.C.-V.); (M.K.)

Collapse

Hauken MA, Velure GK, Müller B, Sekse RJT. Sexual Health and Quality of Life in Cancer Survivors With Pelvic Radiation Injuries. Cancer Nurs 2024;47:E298-E307. [PMID: 37449715 DOI: 10.1097/ncc.0000000000001259] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]

Pilz MJ, Loth FLC, Nolte S, Thurner AMM, Gamper EM, Anota A, Liegl G, Giesinger JM. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population. J Patient Rep Outcomes 2024;8:48. [PMID: 38695992 PMCID: PMC11065800 DOI: 10.1186/s41687-024-00719-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 03/07/2024] [Indexed: 05/05/2024] Open

Abstract

BACKGROUND

General population normative values for the widely used health-related quality of life (HRQoL) measure EORTC QLQ-C30 support the interpretation of trial results and HRQoL of patients in clinical practice. Here, we provide sex-, age- and health condition-specific normative values for the EORTC QLQ-C30 in the French general population.

METHODS

French general population data was collected in an international EORTC project. Online panels with quota samples were used to recruit sex and age groups. Number and type of comorbidities were assessed. Descriptive statistics were used to calculate general population values for each QLQ-C30 scale, separately for sex, age, and presence of one- and more chronic health conditions. A multivariate linear regression model has been developed to allow estimating the effect of sex, age, and the presence for one- and more chronic health conditions on EORTC QLQ-C30 scores. Data was weighted according to United Nation statistics adjusting for the proportion of sex and age groups.

RESULTS

In total, 1001 French respondents were included in our analyses. The weighted mean age was 47.9 years, 514 (51.3%) participants were women, and 497 (52.2%) participants reported at least one health condition. Men reported statistically significant better scores for Emotional Functioning (+9.6 points, p = 0.006) and Fatigue (-7.8 point; p = 0.04); women reported better profiles for Role Functioning (+8.7 points; p = 0.008) and Financial Difficulty (-7.8 points, p = 0.011). According to the regression model, the sex effect was statistically significant in eight scales; the effect of increasing age had a statistically significant effect on seven of the 15 EORTC QLQ-C30 scales. The sex- and age effect varied in its direction across the various scales. The presence of health conditions showed a strong negative effect on all scales.

CONCLUSION

This is the first publication of detailed French normative values for the EORTC QLQ-C30. It aims to support the interpretation of HRQoL profiles in French cancer populations. The strong impact of health conditions on QLQ-C30 scores highlights the importance of considering the impact of comorbidities in cancer patients when interpreting HRQoL data.

Collapse

Aho S, Osterlund E, Ristimäki A, Nieminen L, Sundström J, Mäkinen MJ, Kuopio T, Kytölä S, Ålgars A, Ristamäki R, Heervä E, Kallio R, Halonen P, Soveri LM, Nordin A, Uutela A, Salminen T, Stedt H, Lamminmäki A, Muhonen T, Kononen J, Glimelius B, Isoniemi H, Lehto JT, Lehtomäki K, Osterlund P. Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study). Cancers (Basel) 2024;16:1052. [PMID: 38473410 DOI: 10.3390/cancers16051052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 02/23/2024] [Accepted: 02/27/2024] [Indexed: 03/14/2024] Open

Affiliation(s)

Sonja Aho Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 23, 33520 Tampere, Finland TUNI Palliative Care Research Group, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 23, 33520 Tampere, Finland Palliative Care Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland
Emerik Osterlund Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden Department of Transplantation and Liver Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland
Ari Ristimäki Department of Pathology, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, Haartmaninkatu 3, 00290 Helsinki, Finland Applied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
Lasse Nieminen Department of Pathology, FIMLAB, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland Department of Pathology, University of Tampere, Arvo Ylpön katu 23, 33520 Tampere, Finland
Jari Sundström Department of Pathology, Turku University Hospital, Kiinanmyllynkatu 4-8, 20520 Turku, Finland Institute of Biomedicine, University of Turku, Kiinanmyllynkatu 10, 20520 Turku, Finland
Markus J Mäkinen Department of Pathology, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland Translational Medicine Research Unit, Department of Pathology, University of Oulu, Pentti Kaiteran katu 1, 90570 Oulu, Finland Medical Research Center Oulu, Pentti Kaiteran katu 1, 90570 Oulu, Finland
Teijo Kuopio Department of Pathology, Hospital Nova, Hoitajantie 3, 40620 Jyväskylä, Finland Department of Biological and Environmental Science, University of Jyväskylä, Seminaarinkatu 15, 40014 Jyväskylän yliopisto, Finland
Soili Kytölä Department of Genetics, HUSLAB, HUS Diagnostic Center, Helsinki University Hospital, Haartmaninkatu 3, 00290 Helsinki, Finland Department of Genetics, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
Annika Ålgars Department of Oncology, Turku University Hospital and University of Turku, Hämeentie 11, 20520 Turku, Finland
Raija Ristamäki Department of Oncology, Turku University Hospital and University of Turku, Hämeentie 11, 20520 Turku, Finland
Eetu Heervä Department of Oncology, Turku University Hospital and University of Turku, Hämeentie 11, 20520 Turku, Finland
Raija Kallio Department of Oncology, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland Department of Oncology, University of Oulu, Pentti Kaiteran katu 1, 90570 Oulu, Finland
Päivi Halonen Department of Oncology, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland Department of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
Leena-Maija Soveri Department of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland Home Care, Joint Municipal Authority for Health Care and Social Services in Keski-Uusimaa, Sairaalakatu 1, 05850 Hyvinkää, Finland
Arno Nordin Department of Transplantation and Liver Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland Department of Surgery, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
Aki Uutela Department of Transplantation and Liver Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland Department of Surgery, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
Tapio Salminen Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 23, 33520 Tampere, Finland
Hanna Stedt Department of Oncology, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1A, 70210 Kuopio, Finland
Annamarja Lamminmäki Department of Oncology, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1A, 70210 Kuopio, Finland
Timo Muhonen Department of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland Department of Oncology, South Carelia Central Hospital, Valto Käkelän Katu 1, 53130 Lappeenranta, Finland
Juha Kononen Docrates Cancer Centre, Docrates Hospital, Saukonpaadenranta 2, 00180 Helsinki, Finland Department of Oncology, Hospital Nova, Hoitajankatu 3, 40620 Jyväskylä, Finland
Bengt Glimelius Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden
Helena Isoniemi Department of Transplantation and Liver Surgery, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland Department of Surgery, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
Juho T Lehto TUNI Palliative Care Research Group, Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 23, 33520 Tampere, Finland Palliative Care Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland
Kaisa Lehtomäki Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 23, 33520 Tampere, Finland
Pia Osterlund Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Elämänaukio 2, 33520 Tampere, Finland Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 23, 33520 Tampere, Finland Department of Oncology, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland Department of Oncology, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland Department of Gastrointestinal Oncology, Karolinska Universitetssjukhuset, Eugeniavägen 3, 17176 Solna, Sweden Department of Oncology/Pathology, Karolinska Institutet, Solnavägen 1, 17177 Solna, Sweden

Collapse

Boehmer U, Chang S, Sanchez NF, Jesdale BM, Schabath MB. Cancer survivors' health behaviors and outcomes: a population-based study of sexual and gender minorities. J Natl Cancer Inst 2023;115:1164-1170. [PMID: 37421397 PMCID: PMC10560602 DOI: 10.1093/jnci/djad131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 06/15/2023] [Accepted: 06/29/2023] [Indexed: 07/10/2023] Open

Abstract

BACKGROUND

Most case-control studies compare cancer survivors with general population controls without considering sexual orientation or gender identity. This case-control analysis compared health risk behaviors and health outcomes among sexual and gender minority cancer survivors to those of matched sexual and gender minority participants without cancer (controls).

METHODS

Using data from the 2014-2021 Behavioral Risk Factor Surveillance System, a population-based sample of 4507 cancer survivors who self-identified as transgender, gay men, bisexual men, lesbian women, or bisexual women were 1:1 propensity score matched, using age at survey, race and ethnicity, marital status, education, access to health care, and US census region. Within each sexual and gender minority group, behaviors and outcomes were compared between survivors and participants without cancer, and survivors' odds ratios and 95% confidence intervals calculated.

RESULTS

Gay male survivors had higher odds of depression, poor mental health, limited usual activities, difficulty concentrating, and fair or poor health. Few differences were observed between bisexual male survivors and participants without cancer. Compared with controls, lesbian female survivors had greater odds of overweight-obese status, depression, poor physical health, and fair or poor health. Bisexual female survivors had the highest rates of current smoking, depression, poor mental health, and difficulty concentrating across all sexual and gender minority groups. Statistically significantly different from transgender controls, transgender survivors had greater odds of heavy alcohol use, physical inactivity, and fair or poor health.

CONCLUSIONS

This analysis revealed an urgent need to address the high prevalence of engaging in multiple health risk behaviors and not following guidelines to avoid second cancers, additional adverse outcomes, and cancer recurrences among sexual and gender minority cancer survivors.

Collapse

Zhang J, Kong W, Hu P, Jonker D, Moore M, Ringash J, Shapiro J, Zalcberg J, Simes J, Tu D, O'Callaghan CJ, Liu G, Xu W. Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial. Cancer Med 2023;12:6117-6128. [PMID: 36281472 PMCID: PMC10028035 DOI: 10.1002/cam4.5341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 09/24/2022] [Accepted: 09/30/2022] [Indexed: 12/24/2022] Open

Abstract

INTRODUCTION

Analyzing longitudinal cancer quality-of-life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations ("patient clusters") in the CO.20 clinical trial longitudinal QoL data. Classes were then evaluated for differences in clinico-epidemiologic characteristics and overall survival (OS).

METHODS AND MATERIALS

In CO.20, 750 chemotherapy-refractory metastatic colorectal cancer (CRC) patients were randomized to receive Brivanib+Cetuximab (n = 376, experimental arm) versus Cetuximab+Placebo (n = 374, standard arm) for 16 weeks. EORTC-QLQ-C30 QoL summary scores were calculated for each patient at seven time points, and GMM was applied to identify patient clusters (termed "classes"). Log-rank/Kaplan-Meier and multivariable Cox regression analyses were conducted to analyze the survival performance between classes. Cox analyses were used to explore the relationship between baseline QoL, individual slope, and the quadratic terms from the GMM output with OS.

RESULTS

In univariable analysis, the linear mixed effect model (LMM) identified sex and ECOG Performance Status as strongly associated with the longitudinal QoL score (p < 0.01). The patients within each treatment arm were clustered into three distinct QoL-based classes by GMM, respectively. The three classes identified in the experimental (log-rank p-value = 0.00058) and in the control arms (p < 0.0001) each showed significantly different survival performance. The GMM's baseline, slope, and quadratic terms were each significantly associated with OS (p < 0.001).

CONCLUSION

GMM can be used to analyze longitudinal QoL data in cancer studies, by identifying unobserved subpopulations (patient clusters). As demonstrated by CO.20 data, these classes can have important implications, including clinical prognostication.

Collapse

Belcher BR, Kang DW, Yunker AG, Dieli-Conwright CM. Interventions to Reduce Sedentary Behavior in Cancer Patients and Survivors: a Systematic Review. Curr Oncol Rep 2022;24:1593-1605. [PMID: 35829982 DOI: 10.1007/s11912-022-01313-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/16/2022] [Indexed: 01/27/2023]

Zhou XD, Wei HG, Ai FL. Biofeedback therapy combined with Baduanjin on quality of life and gastrointestinal hormone level in patients with colorectal cancer. World J Gastrointest Oncol 2022;14:1187-1198. [PMID: 35949217 PMCID: PMC9244983 DOI: 10.4251/wjgo.v14.i6.1187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 03/15/2022] [Accepted: 05/17/2022] [Indexed: 02/06/2023] Open

Abstract

BACKGROUND

With the change in people’s lifestyles, the incidence of colorectal cancer (CRC) is increasing. It is essential to study the efficacy of various treatment methods for CRC patients to prevent and treat CRC.

AIM

To investigate the efficacy of biofeedback therapy combined with Baduanjin in improving the quality of life and gastrointestinal hormone levels of patients with CRC.

METHODS

A total of 120 patients with CRC who were admitted to our hospital from June 2020 to June 2021 were included in the study. They were randomly divided into four groups (n = 30): the control group (group A), the biofeedback therapy intervention group (group B), the Baduanjin exercise intervention group (group C), and the combination group (group D). Patients in group A adopted the standard nursing mode and necessary health education. Patients in group B were treated with biofeedback therapy based on routine nursing care. Patients in group C were given Baduanjin intervention for 12 wk based on conventional drug treatment and care. Patients in group D were treated with biofeedback therapy and Baduanjin exercise. In this study, patients’ quality of life, gastrointestinal hormone levels, and clinical efficacy in the four groups were observed at baseline and 12 wk after intervention. Meanwhile, the correlation between gastrointestinal hormone levels and various functional areas of quality of life was analyzed. By comparing the observed indicators of patients in the four groups, the efficacy of biofeedback therapy combined with Baduanjin in improving the quality of life and gastrointestinal hormone levels of patients with CRC was explored.

RESULTS

At baseline, there were no significant differences in quality of life, gastrointestinal hormone levels, or clinical efficacy among the four groups (P > 0.05). Twelve weeks after the intervention, the combination group’s quality of life, gastrointestinal hormone levels, and clinical effectiveness were better than those of the three other groups.

CONCLUSION

On the basis of routine nursing care, patients with CRC combined with biofeedback therapy and Baduanjin exercise can improve the quality of life of patients with CRC and the efficacy of gastrointestinal hormone levels.

Collapse

Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study. Cancers (Basel) 2022;14:cancers14071713. [PMID: 35406485 PMCID: PMC8996978 DOI: 10.3390/cancers14071713] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 02/17/2022] [Accepted: 03/18/2022] [Indexed: 02/01/2023] Open

Liu Y, Xu HF, Zhang X, Yu YQ, Zhao YQ, Zhang SK, Qiao YL. Disease knowledge, medical experience, health-related quality of life and health-care costs among patients with advanced colorectal cancer in China: protocol for a nationwide multicentre survey. BMJ Open 2022;12:e054403. [PMID: 35264348 PMCID: PMC8915290 DOI: 10.1136/bmjopen-2021-054403] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open

Abstract

BACKGROUND

Colorectal cancer (CRC) is one of the most common cancers in China. Most patients have developed advanced stage at diagnosis, leading to a low 5-year survival rate. To optimise prevention strategies, we planned a survey to evaluate the disease knowledge, medical experience and health-related quality of life (HRQOL) before and after the treatment of CRC, and healthcare costs among patients with advanced CRC in China.

METHODS AND ANALYSIS

This is a nationwide, hospital-based, multicentre survey. Nineteen hospitals in seven cities were selected by multistage stratified sampling. Mainland China is divided into seven regions according to the traditional administrative district definition; two cities of each region were selected through simple random sampling, and then one tertiary cancer hospital and one general hospital were selected for each city. More than 4445 patients with CRC in the selected hospitals with stage III or IV will be enrolled in this study. The trained interviewers will collect information through patients' self-report and/or medical records, including demographics and medical history; knowledge about CRC high-risk factors, screening procedure and treatment methods; medical experience on CRC screening, diagnosis and treatment; HRQOL before and after CRC treatment; and costs of CRC. All data will be input by two independent staff and verified using Epidata V.3.1 software. Data validation plan will be made to guide data checking. All statistical analyses will be conducted using SAS V.9.4 and SPSS V.24.0 software.

ETHICS AND DISSEMINATION

The study was approved by the ethics committees of Henan Cancer Hospital, the leading participant hospital. Findings of this study will be disseminated through peer-reviewed open-access journals and presented as posters and/or oral sections in national and international conferences. Results will also be popularised to the public via media or the internet.

Collapse

White VM, Lisy K, Ward A, Ristevski E, Clode M, Webber K, Emery J, Ijzerman MJ, Afshar N, Millar J, Gibbs P, Evans S, Jefford M. Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors. Support Care Cancer 2022;30:5299-5309. [PMID: 35279769 PMCID: PMC9046289 DOI: 10.1007/s00520-022-06914-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 02/12/2022] [Indexed: 12/24/2022]

Abstract

PURPOSE

To examine how socio-demographic, comorbidities and information needs influence quality of life (QoL) outcomes of survivors of breast, colorectal, or prostate cancer, non-Hodgkin lymphoma or melanoma.

METHODS

Cross-sectional postal survey with eligible participants identified through a population-based cancer registry. QoL outcomes were assessed by EQ-5D-5L, social difficulties index (SDI) and, for those employed at diagnosis, current employment. Regression analyses explored associations between outcome variables and cancer type, age, time since diagnosis, residential location, socio-economic disadvantage, comorbidities and unmet information needs. Mediation analyses examined whether comorbidities and information needs explained relationships between outcome variables and socio-economic disadvantage.

RESULTS

2115 survivors participated. Mean EQ-5D-5L scores (mean = 0.84) were similar to population averages and SDI scores were low for the entire sample (mean = 3.80). In multivariate analyses, being aged over 80, greater socio-economic disadvantage, comorbidities and unmet information needs decreased EQ-5D-5L scores. Higher SDI scores were associated with socio-economic disadvantage, comorbidities and unmet information needs. Not being employed was associated with being aged over 50, more comorbidities and socio-economic disadvantage. Comorbidities but not information needs partially mediated the impact of socio-economic disadvantage on EQ-5D-5L and SDI accounting for 17% and 14% of the total effect of socio-economic disadvantage respectively. Neither comorbidities nor information needs mediated the association between socio-economic disadvantage and employment outcomes.

CONCLUSIONS

To improve quality of life, survivorship care should be better tailored to address the needs of individuals given their overall health and impact of comorbidities, their age and type of cancer and not simply time since diagnosis.

Collapse

Affiliation(s)

Victoria M. White grid.1021.20000 0001 0526 7079School of Psychology, Faculty of Health, Deakin University, Geelong, VIC Australia ,2grid.3263.40000 0001 1482 3639Cancer Council Victoria, Melbourne, VIC Australia
Karolina Lisy grid.1055.10000000403978434Australian Cancer Survivorship Centre, Peter MacCallum Cancer Centre, Melbourne, VIC Australia ,4grid.1055.10000000403978434Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, VIC Australia ,5grid.1008.90000 0001 2179 088XSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC Australia
Andrew Ward The Social Research Centre, Melbourne, VIC Australia
Eli Ristevski grid.1002.30000 0004 1936 7857Monash Rural Health, Monash University, Warragul, VIC Australia
Melanie Clode grid.1055.10000000403978434Australian Cancer Survivorship Centre, Peter MacCallum Cancer Centre, Melbourne, VIC Australia
Kate Webber grid.1002.30000 0004 1936 7857School of Clinical Sciences, Monash University, Clayton, VIC Australia ,9grid.419789.a0000 0000 9295 3933Department of Oncology, Monash Health, Clayton, VIC Australia
Jon Emery grid.1008.90000 0001 2179 088XDepartment of General Practice and Centre for Cancer Research, University of Melbourne, Melbourne, Australia
Maarten J. Ijzerman grid.1008.90000 0001 2179 088XSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC Australia
Nina Afshar grid.3263.40000 0001 1482 3639Cancer Council Victoria, Melbourne, VIC Australia ,11grid.1008.90000 0001 2179 088XCentre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Australia
Jeremy Millar grid.267362.40000 0004 0432 5259Alfred Health Radiation Oncology, Alfred and LaTrobe Regional Hospital, Melbourne, VIC 3004 Australia ,13grid.1002.30000 0004 1936 7857School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004 Australia
Peter Gibbs Department of Medical Oncology, Western Health, St. Albans, Victoria, Australia ,15grid.1042.70000 0004 0432 4889Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC Australia
Sue Evans grid.3263.40000 0001 1482 3639Cancer Council Victoria, Melbourne, VIC Australia ,13grid.1002.30000 0004 1936 7857School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004 Australia
Michael Jefford grid.1055.10000000403978434Australian Cancer Survivorship Centre, Peter MacCallum Cancer Centre, Melbourne, VIC Australia ,4grid.1055.10000000403978434Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, VIC Australia ,5grid.1008.90000 0001 2179 088XSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC Australia

Collapse

Symptom burden, psychological distress, and health-related quality of life in cancer survivors with pelvic late radiation tissue injuries. Support Care Cancer 2021;30:2477-2486. [PMID: 34779920 PMCID: PMC8794896 DOI: 10.1007/s00520-021-06684-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 11/04/2021] [Indexed: 12/03/2022]